Data presented at Society for Immunotherapy of Cancer (SITC) 2024
Systemic DNase I combined with
Save time and jump to the most important pieces.
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
4 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
3 - Xenetic Biosciences, Inc. (0001534525) (Issuer)
Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunityDNase based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indicationsXenetic plans to conduct a Phase 1 clinical study of lead asset in locally advanced or metastatic solid tumorsCompany to host update conference call and webcast today, April 27th at 8:30 AM ETFRAMINGHAM, MA / ACCESSWIRE / April 27, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatm
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
10-Q - Xenetic Biosciences, Inc. (0001534525) (Filer)
8-K - Xenetic Biosciences, Inc. (0001534525) (Filer)
SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)
SC 13D/A - Xenetic Biosciences, Inc. (0001534525) (Subject)
SC 13D - Xenetic Biosciences, Inc. (0001534525) (Subject)
Company's Board of Directors Appoint James F. Parslow to Interim Chief Executive Officer FRAMINGHAM, MA / ACCESSWIRE / May 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced the appointment of James Parslow, the Company's Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024."I am a strong believer in the potential of our innovative immune-oncology technologies addressing hard-to-treat cancers. This management change will allow us to focus our resources on driving our pipeline toward
Dr. Bissonnette brings over 25 years in small molecule and biotherapeutic drug discovery and development, oncology and inflammation research and regulatory expertiseFRAMINGHAM, MA / ACCESSWIRE / May 4, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Reid P. Bissonnette, Ph.D. to serve as an executive consultant for translational research and development and to support the advancement of the Company's DNase-based oncology platform. Xenetic's DNase-based oncology platform is designed to target neutrophil extrace
Mr. Cullison brings over 20 years of experience in the pharmaceutical industry with a broad range of expertise across business development and strategic planningFRAMINGHAM, MA / ACCESSWIRE / May 3, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced it has engaged Scott N. Cullison to serve as an executive consultant for business development and to support the advancement of the Company's DNase-based oncology platform. Mr. Cullison brings over 20 years of experience in the pharmaceutical industry. He has amassed a broad range
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(0.79) by 1.27 percent. The company reported quarterly sales of $510.817 thousand which missed the analyst consensus estimate of $650.000 thousand by 21.41 percent. This is a 15.69 percent decrease over sales of $605.844 thousand the same period last year.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.77) per share which beat the analyst consensus estimate of $(0.87) by 11.49 percent. This is a 23 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly earnings of $0.77 per share which beat the analyst consensus estimate of $(0.87) by 188.51 percent. This is a 177 percent increase over losses of $(1.00) per share from the same period last year. The company reported quarterly sales of $671.96 thousand which missed the analyst consensus estimate of $680.00 thousand by 1.18 percent. This is a 37.99 percent increase over sales of $486.97 thousand the same period last year.
Data presented at the AACR Special Conference in Cancer Research: Tumor-body Interactions: The Roles of Micro- and Macroenvironment in CancerResults bolster Company's rationale for incorporating DNase I as an adjunctive treatment to improve therapeutic responses in patients undergoing CAR T cell therapy FRAMINGHAM, MA / ACCESSWIRE / November 21, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric ant
Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indicationsOngoing progress towards first in human clinical study for locally advanced or metastatic solid tumorsStrategic focus on exploratory investigator-initiated studies with institutional partnersEnded the quarter with $6.8 million of cash to fund operations FRAMINGHAM, MA / ACCESSWIRE / November 13, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the third quarter of
Data presented at Society for Immunotherapy of Cancer (SITC) 2024Systemic DNase I combined with